<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Thu, 12 Feb 2026 06:52:18 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667463/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667463/</guid>
      <dc:creator>Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter, randomized phase 3 trial presents a significant survival analysis comparing lobaplatin and fluorouracil to cisplatin and fluorouracil in nasopharyngeal carcinoma, demonstrating non-inferior survival with fewer toxic effects, which has clear practice-changing implications in treatment protocols.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-026-69315-1'&gt;10.1038/s41467-026-69315-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667463/'&gt;41667463&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72-1.43; log-rank p‚Äâ=‚Äâ0.885). The difference between the groups is 1.2% (95% CI -6.7-9.1, pnon-inferiority‚Äâ=‚Äâ0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p‚Äâ=‚Äâ0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except¬†for grades 1-2 peripheral neuropathy (p‚Äâ=‚Äâ0.033), grades 1-2 deafness/otitis (p‚Äâ=‚Äâ0.021), and grades 1-2/3 nephrotoxicity (p‚Äâ=‚Äâ0.005; p‚Äâ=‚Äâ0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.</description>
    </item>
    <item>
      <title>#2 [90/100] Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41667193/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41667193/</guid>
      <dc:creator>You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a multicentre, randomized, open-label phase 3 trial assessing a novel therapeutic approach (camrelizumab) in high-risk nasopharyngeal carcinoma, which has the potential for significant clinical impact and practice-changing implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMJ (Clinical research ed.) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1136/bmj-2025-085863'&gt;10.1136/bmj-2025-085863&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41667193/'&gt;41667193&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.</description>
    </item>
    <item>
      <title>#3 [75/100] Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41671524/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41671524/</guid>
      <dc:creator>Xiang J, Geiger JL</dc:creator>
      <pubDate>Wed, 11 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses insights from a significant trial in recurrent/metastatic head and neck cancer published in a high-impact journal, indicating potential clinical implications and novel findings, though it may not present new clinical data itself.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Xiang J, Geiger JL&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-25-02640'&gt;10.1200/JCO-25-02640&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-11&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41671524/'&gt;41671524&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#4 [75/100] Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41650746/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41650746/</guid>
      <dc:creator>Fuereder T, Klinghammer K, Hahn D, Gr√ºnberger B, Melchardt T, Greil R, Kocher F, Gamerith G, Wagner C, Berchtold L, et al.</dc:creator>
      <pubDate>Thu, 05 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study evaluates a combination therapy in a critical unmet need area for R/M SCCHN after pembrolizumab failure, with a focus on overall response rate and other important clinical outcomes, although it is not a phase 3 trial and published in a lower-tier journal.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Fuereder T, Klinghammer K, Hahn D, Gr√ºnberger B, Melchardt T, Greil R, Kocher F, Gamerith G, Wagner C, Berchtold L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; ESMO open | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.esmoop.2026.106061'&gt;10.1016/j.esmoop.2026.106061&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-05&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41650746/'&gt;41650746&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: No standard second-line treatment has been established for patients with recurrent or metastatic (R/M) squamous-cell carcinoma of the head and neck (SCCHN) progressing after first-line pembrolizumab-based therapy, representing a critical evidence gap in current clinical practice. PATIENTS AND METHODS: Patients with R/M SCCHN of the oropharynx, hypopharynx, larynx, or oral cavity, progressing after first-line pembrolizumab-based regimens, received paclitaxel (PTX) 175 mg/m2 every 21 days plus weekly cetuximab (C) 250 mg/m2 for up to six cycles, followed by C maintenance. The primary endpoint was overall response rate (ORR) at 12 weeks. Secondary endpoints included best overall response (BoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), quality of life, and safety. RESULTS: Fifty-seven patients were enrolled (median age 64 years). Twenty-five patients (43.9%) had a primary tumor in the oropharynx, 17 (29.8%) in the oral cavity, 9 (15.8%) in the hypopharynx, and 6 (10.5%) in the larynx. The ORR was 43.9% [95% confidence interval (CI) 30.7% to 57.6%], the BoR was 47.4% (95% CI 34.0% to 61.0%) with nine (15.8%) complete responses, and the DCR was 71.9% (95% CI 58.5% to 83.0%). DoR was 5.7 months (95% CI 5.1 months-not reached). Median PFS and OS were 5.9 months (95% CI 5.5-8.4 months) and 12.2 months (95% CI 10.5-17.6 months), respectively. Six-month PFS and OS rates were 49.0% and 73.0%, respectively. The most frequent non-hematological treatment-related adverse events were C-associated skin rash (78.9%) and PTX-related polyneuropathy (35.1%). CONCLUSIONS: This is the first prospective trial specifically evaluating PTX plus C after failure of first-line pembrolizumab-based therapy in patients with R/M SCCHN. The observed clinical activity and tolerability support this widely available regimen as a potential standard-of-care option in the absence of randomized evidence in this setting.</description>
    </item>
    <item>
      <title>#5 [75/100] Time to act: a global call for oral cancer prevention and early detection.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41643692/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41643692/</guid>
      <dc:creator>Maret D, Warnakulasuriya S, Epstein JB, Geeraerts T, Vigarios E</dc:creator>
      <pubDate>Sun, 01 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper addresses a critical global health issue regarding oral cancer prevention and early detection, published in a high-impact journal, which may influence clinical practice and public health strategies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Maret D, Warnakulasuriya S, Epstein JB, Geeraerts T, Vigarios E&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The Lancet. Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S1470-2045(25)00708-9'&gt;10.1016/S1470-2045(25)00708-9&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41643692/'&gt;41643692&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#6 [70/100] The Impact of Food Environment on Oropharyngeal Cancer Prognosis in the United States.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41664917/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41664917/</guid>
      <dc:creator>Fei-Zhang DJ, Kim H, Chelius DC, Sheyn AM, Rastatter JC, D'Souza JN</dc:creator>
      <pubDate>Tue, 10 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This large retrospective study analyzes the impact of food environment on oropharyngeal cancer prognosis using a substantial sample size of over 70,000 patients, providing novel insights into socioeconomic factors affecting mortality, although it lacks the prospective design and definitive clinical implications of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Fei-Zhang DJ, Kim H, Chelius DC, Sheyn AM, Rastatter JC, D'Souza JN&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70195'&gt;10.1002/hed.70195&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41664917/'&gt;41664917&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Nutrition and socioeconomic status are well-established risk factors for oropharyngeal squamous cell carcinoma (OPSCC) progression and mortality, but the impact of the food environment remains largely understudied. METHODS: In this retrospective study, race/ethnicity-stratified inferential and mediation analyses assessed selected clinical outcomes for 70‚Äâ581 OPSCC patients from the Surveillance, Epidemiology, and End Results. We examined the effects of Food Environment Atlas scores composited from 282-county-level variables, adjusted for the effects of traditional social determinants of health. RESULTS: Worse food environments were modestly associated with increased risk of overall mortality (aHR-1.03, 95% CI, 1.02-1.04), 3-year overall mortality (aOR-1.04, 95% CI, 1.03-1.05), and advanced stage at diagnosis (aOR-1.02, 95% CI, 1.01-1.03) in the whole sample, with exacerbated associations across all outcomes among non-White patients. The food environment was not significantly associated with having more than one primary tumor at diagnosis. Traditional social determinants of health partially mediated mortality, but not staging effects. CONCLUSIONS: Poor food environments were modestly associated with increased OPSCC mortality and advanced staging, with exacerbated effects in non-White patients. These retrospective findings support investigations into specific mechanisms of food environment inequity on OPSCC outcomes to guide targeted public health interventions such as subsidized transportation.</description>
    </item>
    <item>
      <title>#7 [70/100] A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41672251/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41672251/</guid>
      <dc:creator>Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large, multicenter validation of a DNA methylation signature in HPV-negative HNSCC patients, which has important clinical implications for predicting distant metastasis after postoperative radiochemotherapy, though it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Tawk B, Halec G, Rein K, Schwager C, Knoll M, Wirkner U, Held T, Weykamp F, Liermann J, Hoerner-Rieber J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111433'&gt;10.1016/j.radonc.2026.111433&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41672251/'&gt;41672251&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (n‚ÄØ=‚ÄØ134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HR‚ÄØ=‚ÄØ2.34, p‚ÄØ=‚ÄØ0.03) and distant metastasis (DM, HR‚ÄØ=‚ÄØ4.3, p‚ÄØ=‚ÄØ0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patient≈õ age, gender, smoking status, tumor stage, and high-risk features (ECE&amp;/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.</description>
    </item>
    <item>
      <title>#8 [70/100] Androgen Receptor Signaling Induces CD8‚Å∫ T Cell Dysfunction that is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41661680/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41661680/</guid>
      <dc:creator>Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents important insights into the role of androgen receptor signaling in CD8‚Å∫ T cell dysfunction in head and neck squamous cell carcinoma, with potential implications for androgen deprivation therapy, but it lacks the large sample size or randomized controlled trial design that would elevate its impact further.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wang Q, Tan Z, Zheng C, Xu J, Li Q, Hong S, Yu D, Hu X, Wang J, Jiang L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/0008-5472.CAN-25-2384'&gt;10.1158/0008-5472.CAN-25-2384&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41661680/'&gt;41661680&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Head and neck squamous cell carcinoma (HNSCC) exhibits a distinct sex disparity in incidence, with a higher incidence in males than females. Recent studies have suggested that this difference persists even after accounting for smoking and alcohol use, highlighting the need to elucidate the underlying biological mechanisms. In this study, we demonstrated that sex differences in HNSCC are androgen-dependent and identified androgen receptor (AR) signaling as a key regulator of the tumor immune microenvironment by modulating CD8‚Å∫ T cell differentiation and function. Mechanically, early growth response 4 (EGR4) functioned as a direct downstream transcriptional effector of AR that induced CD8‚Å∫ T cell dysfunction. Clinically, androgen deprivation therapy (ADT) was an effective therapeutic strategy in HNSCC, suppressing tumor growth in mice while improving intratumoral CD8‚Å∫ T cell function. Moreover, combining ADT with immune checkpoint inhibitors led to improved antitumor efficacy. Together, these findings reveal ADT as a promising therapeutic approach to enhance the antitumor activity of sex-biased CD8‚Å∫ T cells in HNSCC, which could inform the development of sex-biased immunotherapies for treating HNSCC patients.</description>
    </item>
    <item>
      <title>#9 [70/100] The impact of tobacco cessation on buccal mucosa cancer risk: A multi-centre case-control study in India.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41657059/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41657059/</guid>
      <dc:creator>Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S</dc:creator>
      <pubDate>Mon, 09 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multi-centre case-control study with a large sample size provides important insights into the impact of tobacco cessation on buccal mucosa cancer risk, which has significant clinical implications, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, Dikshit R, Lewington S, Mhatre S&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ijc.70372'&gt;10.1002/ijc.70372&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41657059/'&gt;41657059&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;While the association between tobacco consumption and oral cancer is well established, the effect of tobacco cessation, particularly chewing tobacco, is less extensively studied. We aim to explore the effect of tobacco cessation on the risk of buccal mucosa cancer (BMC). A case-control study was conducted across five cancer centres in India. We enrolled 2320 BMC and 2302 frequency-matched controls. Information was collected on smoking and chewing (products, duration and quitting). Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) of the effect of tobacco cessation compared to current users, after adjusting for potential confounders. For both smoking and chewing, the odds reduced rapidly after 5‚Äâyears of quitting, so that those who had quit smoking ‚â•10‚Äâyears ago had only 0.39 (95% CI 0.28-0.54) the odds of BMC compared to those who continued to smoke, and those who quit chewing ‚â•10‚Äâyears ago had 0.58 (95% CI 0.43-0.81) the odds of BMC compared to those who continued to chew. Chewing with areca nut was associated with almost double the risk of chewing without (OR 1.86, 95% CI 1.53-2.26) but the rate of reduction of risk with quitting was similar. These findings show clearly the benefits of quitting and inform policies that emphasize chewing tobacco cessation, given its widespread prevalence in India.</description>
    </item>
    <item>
      <title>#10 [70/100] Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41655423/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41655423/</guid>
      <dc:creator>Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G</dc:creator>
      <pubDate>Sat, 07 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important prognostic factor in HNSCC and provides valuable insights into survival impact, but it is based on retrospective data and does not present novel therapeutic findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Singh SP, Prasad S, Dean PM, Kujur AL, Jaiswal G&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107862'&gt;10.1016/j.oraloncology.2026.107862&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-07&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41655423/'&gt;41655423&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Extranodal extension (ENE) of cervical lymph node metastases is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis evaluated the survival impact of ENE in HNSCC and identified global research trends relevant to this research field through a complementary bibliometric analysis. MATERIALS AND METHODS: ScienceDirect, PubMed, and Scopus were systematically searched during 2000-2025. A systematic review and a meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. A Scopus-based bibliometric analysis was conducted using the Biblioshiny package of R to identify and map the publication trends, influential authors, and major institutional contributions between 2010 and 2025. RESULTS: Of the 839 retrieved records, 711 studies were screened, and 16 studies comprising approximately 3900 patients met all inclusion criteria. The bibliometric analysis of 120 Scopus-indexed publications demonstrated a marked increase in ENE-related research from 2015 onward, driven primarily by institutions in Australia, Taiwan, and South Korea. Keyword mapping indicated expanding intersections of ENE research with radiomics, prognostic modelling, and refinement of staging systems. Meta-analysis confirmed a significant association between ENE and adverse survival outcomes. Subgroup analyses showed consistently poor prognostic implications across both pathologic and radiologic ENE assessments. CONCLUSION: ENE in cervical lymph node metastases is an independent and strong predictor of adverse survival in HNSCC. The increasing global attention to ENE highlights its crucial role in multidisciplinary oncologic management. Therefore, standardized pathological and imaging-based assessment of ENE is essential for developing superior prognostic models and optimizing future treatment planning strategies.</description>
    </item>
  </channel>
</rss>
